Exploring a new treatment target for advanced prostate cancer
Testing ATAD2 as a new therapeutic target for advanced prostate cancer
This study is looking at a new way to treat advanced prostate cancer that doesn't respond to regular treatments by testing a special type of medicine that targets a protein called ATAD2, with the hope of finding better options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10902612 on NIH RePORTER |
What this research studies
This research investigates the potential of ATAD2 as a therapeutic target for advanced prostate cancer, particularly in cases that have become resistant to standard treatments. The approach involves testing ATAD2 inhibitors in pre-clinical models to assess their effectiveness in slowing down or stopping tumor growth. By understanding how ATAD2 contributes to the progression of prostate cancer, the study aims to develop new treatment strategies that could improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer, especially those whose cancer has progressed to castration-resistant prostate cancer or neuroendocrine prostate cancer.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer, particularly those with treatment-resistant forms of the disease.
How similar studies have performed: Previous studies have shown promising results with similar approaches targeting ATAD2 in cancer treatment, indicating potential for success in this area.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Stoyanova, Tanya I — University of California Los Angeles
- Study coordinator: Stoyanova, Tanya I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.